Pentostatin (Nipent) in T-cell lymphomas. Semin Oncol 2000 Apr;27(2 Suppl 5):64-6
Date
07/06/2000Pubmed ID
10877055Scopus ID
2-s2.0-0033918832 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Pentostatin (Nipent; SuperGen, San Ramon, CA), which is highly lymphocytotoxic, is an active agent in hairy cell leukemia. We therefore initiated a trial of this agent in T-cell lymphomas. Pentostatin was administered at a dose of 3.75 or 5.0 mg/m2/d intravenously for 3 days every 3 weeks to heavily pretreated patients with cutaneous and peripheral T-cell lymphomas. To date, there are 24 evaluable patients in the trial. Seventeen of these individuals have responded (complete or partial remission). The most common toxicities included granulocytopenia, nausea, renal insufficiency, CD4 suppression, and delayed herpes zoster. Pentostatin is an active agent in this group of diseases and merits further exploration.
Author List
Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Agranulocytosis
Antibiotics, Antineoplastic
CD4-Positive T-Lymphocytes
Female
Herpes Zoster
Humans
Immunosuppressive Agents
Injections, Intravenous
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Peripheral
Male
Middle Aged
Nausea
Pentostatin
Remission Induction
Renal Insufficiency
Skin Neoplasms
